WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Aadil Wani, Showkat Ahmad Kadla, Ashaqullah Bhat, Rajinder Kaur ,Gulzar Ahmad Bhat, Muzamil Ali, Nida Sadiq, Muzamil Ashraf Makhdoomi, Bashir Ahmad Ganai*


Hypertension is the premier cause of the disease burden in developed as well as developing countries of the world. Hypertension affects approximately 37-55% population of the developed countries and the genetic susceptibility to it could be an outcome of the inherited differences in the capacity of sodium retention.CYP3A5 enzyme has been implicated in the regulation of blood pressure (BP) and thus, may serve as a potential risk factor for the development of hypertension. Carriers of the CYP3A5*1 allele had high, whereas homozygous carriers of the CYP3A5*3 allele exhibit low CYP3A5 expression in the kidney, where it represents the major isoform of the CYP3A family. The aim of the present hospital based case control study was to investigate the association of the CYP3A5*1 rs776746 (6986 𝐴→) allele with BP in hypertension cases and healthy controls in a sample of Kashmiri population, a north India state. The study included 150 hypertension patients (78 males and 72 females; age (mean ± S.D) 60.55 ± 11.19 years) and normotensive controls (79males and 71 females; age (mean ± S.D) 60.11±9.92 years). The distribution of CYP3A5 genotype in hypertension cases and controls was assessed by PCRRFLP method. Logistic regression was used to assess the relationship between CYP3A5 genotype and the risk of essential hypertension. Although CYP3A5*1 genotype was higher in cases (10%) than in controls (3.66%), however, it did not reach a statistically significance It was found that CYP3A5*1 carriers showed decrease in systolic blood pressure (SBP ) by 6.02 mmHg and an increase in diastolic blood pressure (DBP) by 2.50 mmHg, but, the results were not statistically significant. So, there is no association of CYP3A5*1 with the risk of essential hypertension.

Keywords: CYP3A5, SBP, DBP, gene polymorphism.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More